Tuba Banaz

Dr. Tuba Banaz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ADAnushka Dongre
Anushka Dongre
MRMohammad Rashidian
Mohammad Rashidian
EEElinor Ng Eaton
Elinor Ng Eaton
FRFerenc Reinhardt
Ferenc Reinhardt
PTPrathapan Thiru
Prathapan Thiru
RWRobert A. Weinberg
Robert A. Weinberg
The epithelial-to-mesenchymal transition, which conveys epithelial (E) carcinoma cells to quasi-mesenchymal (qM) states, enables them to metastasize and acquire resistance to certain treatments. Murine tumors composed of qM mammary carcinoma cells assemble an immunosuppressive tumor microenvironment (TME) and develop resistance to anti-CTLA4 immune-checkpoint blockade (ICB) therapy, unlike their E counterparts. Importantly, minority populations of qM cells within a tumor can cross-protect their more E neighbors from immune attack. The underlying mechanisms of immunosuppression and cross-protection have been unclear. We demonstrate that abrogation of qM carcinoma cell–derived factors (CD73, CSF1, or SPP1) prevents the assembly of an immunosuppressive TME and sensitizes otherwise refractory qM tumors partially or completely to anti-CTLA4 ICB. Most strikingly, mixed tumors in which minority populations of carcinoma cells no longer express CD73 are now sensitized to anti-CTLA4 ICB. Finally, loss of CD73 also enhances the efficacy of anti-CTLA4 ICB during the process of metastatic colonization. Significance: Minority populations of qM carcinoma cells, which likely reside in human breast carcinomas, can cross-protect their E neighbors from immune attack. Understanding the mechanisms by which qM carcinoma cells resist antitumor immune attack can help identify signaling channels that can be interrupted to potentiate the efficacy of checkpoint blockade immunotherapies. This article is highlighted in the In This Issue feature, p. 995

24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.

23 April 2026 in European Radiology
Verified
Journal Article
Closed access
PDF file
BKBurak Kocak
Burak Kocak
TBTuba Banaz
Tuba Banaz
MSMerve Söyleyici
Merve Söyleyici
FKFadime Kose
Fadime Kose
AKAli Keles
Ali Keles
IMIsmail Mese
Ismail Mese

28 May 2026 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
SOSercin Ozkok
Sercin Ozkok
BKBanu Kose
Banu Kose
IYIlker Kemal Yucel
Ilker Kemal Yucel
TGTansu Golcez
Tansu Golcez
MUMuhammad Umair
Muhammad Umair
KPKerem Pekkan
Kerem Pekkan
Congenital heart disease (CHD) often requires device implantation during childhood, when somatic growth and changing haemodynamics place particular demands on permanent implants. Metallic stents and nitinol occluders are effective, but their lifelong persistence can complicate repeat interventions, limit imaging surveillance, and interfere with growth-related remodelling. This review examines the rationale, current evidence, biomechanical constraints, and translational challenges of biodegradable stents and occluders in CHD. These devices aim to provide temporary mechanical support followed by controlled resorption, thereby reducing the burden of permanent foreign material and preserving future interventional options. Translation to congenital practice is, however, not straightforward, as early structural integrity must be balanced against predictable degradation, adequate endothelialisation, and compatibility with somatic growth. Experience from adult coronary bioresorbable scaffolds cannot be directly extrapolated to paediatric anatomies or timelines. Biodegradable septal occluders have accumulated more clinical experience and appear closer to routine use, whereas biodegradable vascular stents remain largely investigational and lack sufficient long-term outcome data to support broader adoption. Further long-term studies in paediatric and congenital populations are needed before biodegradable implants can be recommended as standard alternatives to permanent devices in CHD.

1 January 2026 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
IMIsmail Mese
Ismail Mese
SGSaime Turgut Gunes
Saime Turgut Gunes
OCOzge Coskun
Ozge Coskun
AKAli Keles
Ali Keles
TBTuba Banaz
Tuba Banaz
BKBurak Kocak
Burak Kocak
Mese I, et al. Korean J Radiol. 2026 ;27:e72. https://doi.org/10.3348/kjr.2026.0505

3 April 2023
Verified
Other
Open access
ADAnushka Dongre
Anushka Dongre
MRMohammad Rashidian
Mohammad Rashidian
EEElinor Ng Eaton
Elinor Ng Eaton
FRFerenc Reinhardt
Ferenc Reinhardt
PTPrathapan Thiru
Prathapan Thiru
RWRobert A. Weinberg
Robert A. Weinberg
This file contains Supplementary Figures 1-8 and Supplementary Tables #1-2